Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004825-87

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the efficacy of a 6-month daily application of 0.1% , 0.5% and 1% tazarotene fingernail lacquer in fingernail psoriasis, using Expert Physician Global Assessment (EPGA) corresponding to a blinded assessment of photographs using a 6-point scale.


Critère d'inclusion

  • Psoriasis of the skin is frequently accompanied by nail changes: between 10 and 78% of psoriatic patients suffer from changes of the nails. More than 50% of patients with nail psoriasis have pain because of nail changes, and nearly 60% experience limitations in daily activities. Conventional therapies (e.g., topical agents, triamcinolone acetonide injections, cyclosporine, methotrexate, retinoids, and phototherapy) have limited efficacy, and many have tolerability concerns